Sentence examples for explain the poor outcome from inspiring English sources

In terms of game theory, the fact that the Greeks and Germans have different economic interests is not enough to explain the poor outcome of negotiations to date.

Thus, in order to find causal relationships that can explain the poor outcome of elderly patients after burns, we need more evidence.

Unfortunately, the main genetic alteration, MYCN amplification, does not explain the poor outcome of all neuroblastoma patients, suggesting that additional biomarkers of disease progression are still needed.

The high association between ER and BCL-2 is already documented [ 42] and observed in this study which might explain the poor outcome observed amongst those patients revealing high levels of HER2/HER3 and ER+ status.

The baseline characteristics between patients with NGT and abnormal OGTT were not significantly different, while patients with known diabetes had significantly higher co-morbidity as seen with, for example, previous myocardial infarction, higher serum creatinine and BMI, which, in addition to higher age, can at least partly explain the poor outcome in these patients.

And the new research suggests that whites are more likely than blacks to have tumors linked to the virus, which may explain the poor outcomes of African-Americans with HPV-negative tumors.

These patients may then be denied tumour-specific chemotherapy or molecularly targeted therapy, which may further explain the poor outcomes in this group.

Additionally, among patients with multiple postoperative complications physicians may record more comorbidities in the discharge summary to explain the poor outcomes, while this may not be detailed in patients with an uncomplicated postoperative recovery.

Interestingly, socially phobic women were less likely than women without social phobia to obtain an Alcoholics Anonymous sponsor, which may help explain the poor outcomes for TSF among this subgroup.

For RMS, this may partly be due to a higher proportion of TYA patients with more aggressive histologies, but this cannot entirely explain the poor outcomes in TYAs with bone and soft tissue sarcomas in general.

Previous literature has noted a reluctance to prescribe and use very high doses of U-100 insulin as well as a reduced physiological response among patients on such regimens; 38 this evidence may help to explain the poor outcomes among the highest dose patients in our study.